At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Bomedemstat (drug)
- How long the study runs
- Study runs about 127 months (dates as stated)
- About the drug or intervention
- Bomedemstat — drug: 10, 15, 20, and 50 mg oral capsules
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at the safety and how well bomedemstat (also called MK-3543-017) works in people with blood conditions such as essential thrombocythemia, polycythaemia vera and myelofibrosis. It is for people who have already taken bomedemstat in an earlier study run by Imago BioSciences (part of Merck & Co., Inc. or MSD) and are set to move into this study. The sponsor is Merck Sharp & Dohme LLC.
Who can take part
- You took part in a bomedemstat study run by Imago BioSciences (part of Merck & Co., Inc.) or MSD, and have been marked as ready to join this study
- You had at least 6 months of bomedemstat treatment in the IMG-7289-202/MK-3543-005 study, are tolerating it safely, and your doctor believes you are benefiting from it
- If you joined from a different earlier study (for essential thrombocythemia or polycythaemia vera), your blood counts must have reached a confirmed remission, you must be tolerating bomedemstat safely, and your doctor believes you are benefiting from it
- You are not currently on a dose hold (a pause in your treatment)
- You can swallow tablets and follow instructions for taking bomedemstat at home
Who may not be able to
- You have taken medicines that are not allowed alongside this study treatment
- You are taking part, or planning to take part, in another research study
- You missed more than 10% of your assigned doses in your earlier bomedemstat study, not counting pauses agreed by your doctor
What taking part involves
- • Taking bomedemstat as an oral (swallowed) medicine at home
- • Following instructions for taking your doses at home
Time commitment: Not stated — ask the trial team (the data only says treatment is taken by mouth at home; number of visits and study length are not stated)
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 400
- Started
- 2024-05-23
- Last checked
- 2026-04
Plain English Summary
What is this study?
- • Testing a new treatment for thrombocythemia, essential
- • Phase3 - 400 participants
- • The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with thrombocythemia, essential
Where?
- • London - Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
- • Boston - Boston Pilgrim Hospital ( Site 3403)
- • London - University College London Hospital ( Site 3400)
- • London - Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck \& Co., Inc.) or MSD, and...
- ✓Is not currently on a dose hold
- ✓Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
Who cannot take part
- ✗Has received prohibited concomitant medications
- ✗Ongoing or planned participation in another investigational study
- ✗Has noncompliance in prior bomedemstat study receiving \<90% of assigned doses excluding suspensions or holds as...
See the full criteria
Where Is This Study? (4 UK sites)
Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
London W12 0HS, United Kingdom
Boston Pilgrim Hospital ( Site 3403)
Boston PE21 9QS, United Kingdom
University College London Hospital ( Site 3400)
London NW1 2PG, United Kingdom
Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
London SE1 9RT, United Kingdom
How to Get in Touch
Toll Free Number
Sponsor contactCONTACT